Skip to search formSkip to main contentSkip to account menu

lifitegrast

Known as: (2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid, L-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Ophthalmic SolutionPhenylalanineSulfones

Narrower (1)

SAR 1118
analogs & derivativeslifitegrast 50 MG/ML Ophthalmic Solutionlifitegrast 50 MG/ML Ophthalmic Solution [Xiidra]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies
2018
2018
Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease.
Studies have shown that lifitegrast will reduce the symptoms of dry eye disease in some patients, although the benefit is… 
2018
2018
Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report
Background: To describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR… 
Review
2017
Review
2017
Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry… 
2017
2017
Ocular distribution and pharmacokinetics of lifitegrast following repeat topical ocular dose administration to pigmented rabbits
2016
2016
Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials
Abstract Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of… 
2016
2016
Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
Dry eye disease is an extremely common condition affecting millions worldwide. The underlying pathophysiological mechanism is… 
2016
2016
Shire gets FDA nod for Xiidra (lifitegrast) for dry eye
Shire plc obtained U.S. Food and Drug Administration (FDA) approval for Xiidra (lifitegrast ophthalmic solution) 5%, a twice… 
2014
2014
Lifitegrast yields treatment benefit across symptom endpoints
A phase III clinical trial of lifitegrast 5% ophthalmic solution for treatment of dry eye showed treatment benefit across all… 
2012
2012
SARcode reports phase III results for lifitegrast
SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)